Product Developments, Partnerships and Validated Clinical Trials Help Diversify Today's Treatments - Research Report on Varian, Align Technology, Volcano, Wright Medical Group, and Cyberonics PR Newswire NEW YORK, June 6, 2013 NEW YORK, June 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom . Today, Wall Street Reports announced new research reports highlighting Varian Medical Systems Inc. (NYSE: VAR), Align Technology Inc. (NASDAQ: ALGN), Volcano Corporation (NASDAQ: VOLC), Wright Medical Group Inc. (NASDAQ: WMGI), and Cyberonics Inc. (NASDAQ: CYBX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Varian Medical Systems Inc. Research Report On May 22, 2013, Varian Medical Systems Inc. (Varian Medical) announced that it received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for Varian's diagnostic X-ray image processing workstation that combines radiography/fluoroscopy (RF) and digital radiography (DR) capabilities on one platform. "Nexus is Varian's 6th generation image processing platform," said Carl LaCasce, Vice President and General Manager for Varian's Imaging Products business. "It's an updated platform designed to provide our customers with a universal system that addresses both dynamic and static imaging modalities, as well as CCD camera based fluoroscopy." The Nexus system enables an operator to acquire, display, process, transmit, export, or print high resolution X-ray images. "Varian views its Nexus product as a cost effective, reliable solution to support a wide range of our customers' requirements," concluded LaCasce. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [ http://www.wsreports.com/r/full_research_report/b046_VAR ] -- Align Technology Inc. Research Report On June 3, 2013, Align Technology Inc. (Align Technology) and Henry Schein Dental, the US dental business of Henry Schein, Inc., jointly announced the introduction of Realine, an entry level, five-stage clear aligner product designed for very minor crowding and spacing issues that general practitioner (GP) dentists see in their practices every day. "This is Align's first exclusive distribution partnership in North America for a clear aligner product," said Greg Morrow, Align Technology Vice President and General Manager for Invisalign. "Henry Schein Dental provides the reach, scalability, and strong long term relationships with GP dentists to help Align reach an untapped market of more than 80,000 dentists with Realine, while still allowing us to maintain our primary focus on Invisalign providers and comprehensive orthodontic treatment through Invisalign." Realine will be available in the US by mid-June 2013 exclusively through Henry Schein Dental, the world's largest provider of healthcare products and services to office-based dental practitioners. The Full Research Report on Align Technology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [ http://www.wsreports.com/r/full_research_report/67be_ALGN ] -- Volcano Corporation Research Report On May 23, 2013, Volcano Corporation (Volcano) announced its preliminary results from the Adenosine Vasodilator Independent Stenosis Evaluation (ADVISE) II trial during the clinical trial session at EuroPCR 2013. "An important step in the validation of any new technology is to identify a hypothesis based on observations, and to then prospectively test the hypothesis in a large number of centers to see if the observations translate to real-world practice," commented Javier Escaned, MD, PhD, Interventional Cardiologist at Hospital Clínico San Carlos, Madrid, Spain. "The ADVISE II study is the first prospective test of the true iFR algorithm that is analyzed through an independent physiology core lab (Cardialysis, Rotterdam, Netherlands). These preliminary results show that the prior observations can be replicated prospectively, and that a Hybrid iFR/FFR approach can provide a greater than 90% agreement with FFR while saving the use of hyperemic agent in more than half of patients." The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [ http://www.wsreports.com/r/full_research_report/1aba_VOLC ] -- Wright Medical Group Inc. Research Report On May 14, 2013, Wright Medical Group Inc. (Wright Medical Group) announced that its shareholders have approved a proposal to increase the size of the Company's Board to include ten directors. Douglas G. Watson has been elected as Wright Medical's tenth Director, with immediate effect. Mr. Watson currently serves as Chairman of the Board of OraSure Technologies, Inc., as a Lead Director of Dendreon Corporation, and a Director of Delcath Systems, Inc. "We are delighted to have someone with Doug's proven leadership skills and extensive operational expertise join our board," said David Stevens, Chairman of the Board of Wright Medical. "As a past director of BioMimetic Therapeutics, Doug brings to our Board of Directors an institutional knowledge of BioMimetic's products and operations that will be of great value as the company's management team continues to execute its transformational plan, as well as our strategy of building a world-class biologics platform and accelerating growth in our foot and ankle business." The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [ http://www.wsreports.com/r/full_research_report/1f8a_WMGI ] -- Cyberonics Inc. Research Report On May 28, 2013, Cyberonics, Inc. (Cyberonics) announced the receipt of a letter from the Centers of Medicare and Medicaid Services (CMS) declining the Company's request to reconsider the 2007 National Coverage Determination for the treatment-resistant depression indication. "Cyberonics is very disappointed in the position taken by CMS that the new evidence accumulated over the past five years and recently published in four peer-reviewed journals does not support reconsideration of the non-coverage decision. We believe the total body of evidence that began appearing in the scientific literature in 1998 presents compelling rationale for access to VNS Therapy in a very ill subpopulation of Medicare beneficiaries," said Dan Moore, Cyberonics' President and Chief Executive Officer. "The company plans to work with other interested parties to continue to pursue access to this important therapeutic option for patients who could benefit from VNS Therapy, including carefully evaluating all options for appealing this decision." The Company will provide additional information at its financial results conference call on June 5, 2013. The Full Research Report on Cyberonics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [ http://www.wsreports.com/r/full_research_report/a55c_CYBX ] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com . 5.For any urgent concerns or inquires , please contact us at compliance@EquityNewsNetwork.com . 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Product Developments, Partnerships and Validated Clinical Trials Help Diversify Today's Treatments - Research Report on Varian,
Press spacebar to pause and continue. Press esc to stop.